GC
Therapeutic Areas
Transgene SA Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BT-001 | Solid Tumors | Phase 1/2 |
| TG4001 | HPV-positive cancers (head & neck, anogenital) | Phase 2 |
| TG4050 | Ovarian Cancer (adjuvant) | Phase 1 |
| TG6002 | Advanced Gastrointestinal Cancers | Phase 1/2 |
| TG6050 | Non-small Cell Lung Cancer (NSCLC) | Preclinical |
| myvac®-based Neoantigen Vaccines | Various Solid Tumors (Personalized) | Phase 1 |
Leadership Team at Transgene SA
HB
Hedi Ben Brahim
Chairman of the Board of Directors
AR
Alessandro Riva, M.D.
Chief Executive Officer (Interim)
CA
Christophe Ancel
Chief Financial Officer
MA
Maïté Angleys
Chief Business Officer
EQ
Eric Quéméneur, Ph.D.
Executive Vice President, Chief Scientific Officer
JB
Johanna Bono
Vice President, Clinical Development
JF
John Felitti
Vice President, Business Development
BP
Brigitte Prou
Vice President, Human Resources
KL
Karine Lignel
Vice President, Corporate Communications